Immunogenicity of recombinant Mycobacterium smegmatis expressing antigen 85b epitopes as a potential tuberculosis vaccine candidate
Tuberculosis (TB) remains a major worldwide health problem which causes more than 1.3 million deaths annually. The development of a new vaccine as a replacement of Bacille Calmette Guerin (BCG) or to improve its efficacy is one of the goals mooted by the World Health Organization (WHO) to control TB...
Saved in:
| Main Author: | |
|---|---|
| Format: | Thesis Book |
| Language: | English |
| Published: |
2017.
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Tuberculosis (TB) remains a major worldwide health problem which causes more than 1.3 million deaths annually. The development of a new vaccine as a replacement of Bacille Calmette Guerin (BCG) or to improve its efficacy is one of the goals mooted by the World Health Organization (WHO) to control TB. Mycobacterium smegmatis (M smegmatis) is nonpathogenic and commensal in humans, which shares many characteristics with Mycobacterium tuberculosis (M tuberculosis). Mycobacterial vectors including M smegmatis have been successfully used in the development of experimental vaccines against TB. In the current study, recombinant M smegmatis expressing selected Ag85B epitopes (PI, P2 and P3) was constructed (rMs064). The immunomodulatory effects of rMs064 were evaluated in J774A.I murine macrophage cells. Our results demonstrated the capacity of rMs064 to induce the expression of the macrophage activation markers; MHC class nand CD40 molecules, and the production of IL-6, IL-IO and IL-12p70 cytokines. Both rMs064 and M smegmatis transformed with the empty plasmid (rMsOI2 as a control) were capable to induce phagocytic and mycobactericidal activity in macrophages as well as the production of IL-l |
|---|